Perceiv AI to attend J.P. Morgan Healthcare Conference and AD/PD in Q1 2024
- S&P 500, Nasdaq close at fresh records on AI boost, easing yields
- Goldman removes Apple stock from 'US Conviction List - Directors' Cut'
- Boeing in talks to acquire Spirit AeroSystems, analysts discuss 'negative' financial benefits
- Stocks climb, yields fall as data supports rate cut bets
- Dell tops estimates on boost from AI-led server demand, shares jump premarket
As a leading innovator in precision medicine and Alzheimer's disease, Perceiv AI is committed to developing its prognostic platform Foresight™. This versatile multimodal platform is designed to predict disease progression, with a primary focus on Alzheimer's disease. Perceiv AI aims to offer a comprehensive understanding of individual patient's disease progression, facilitating the development of new therapies and supporting timely diagnosis.
The Alzheimer's disease space has experienced significant momentum in the past year, with Eisai's Lecanemab receiving full FDA approval and CMS reimbursement last July, and Eli Lilly's Donanemab showing promising Phase III trial results last October.
In anticipation of the conference, Dr.
Furthermore, Perceiv AI is pleased to announce its participation at the International Conference on Alzheimer's and Parkinson's Disease and related neurological disorders (AD/PD), scheduled to take place in
The company will present an oral session titled "Use of Foresight AD to Reduce Screen Failure Rates Due to Biomarker Cut-Offs in Early Alzheimer's Disease Trials."
Session Name: Biomarkers in Clinical Use Across Dementias
Room: Auditorium VI+VII
For more information on the session: https://cslide.ctimeetingtech.com/adpd24/attendee/confcal/show/session/103
About Perceiv AI
Perceiv AI is an AI-driven precision medicine company developing a powerful multimodal prognostic platform named Foresight to forecast disease progression in age-related diseases such as Alzheimer's disease. By providing a window into individual patients' disease progression, Perceiv AI aims to accelerate and de-risk the development of new therapies while enabling timelier diagnoses.
For more information, please visit www.perceiv.ai
SOURCE Perceiv AI
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Flash News: OKX Ventures Announces Series A Investment in Taiko, a Decentralized, Ethereum-Equivalent ZK-Rollup
- XXIV Habano Festival: HABANOS, S.A. CLOSES THE XXIV HABANO FESTIVAL WITH A TRIBUTE TO TRINIDAD ON ITS 55th ANNIVERSARY
- Froggies Token Has Added to Their Ecosystem, Through the Release of the Revenue Generating Telegram Bots Raid-Father and Cracker Jack
Create E-mail Alert Related CategoriesPRNewswire, Press Releases
Related EntitiesJPMorgan, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!